News Sentiment

IMDX sentiment intelligence

Insight Molecular Diagnostics Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 54 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Diagnostics & Research Read-through group
Latest close 4.74 Week of 17 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

83/100 classification confidence.

Company focus 54

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-6.7% over one week, -12.9% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Neutral

Qiagen stock trades steadily as diagnostics demand supports earnings and cash flow

Market Reaction

Price moving ahead of tone

67/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 83/100 classification
One-week reaction -6.7% Price reacting lower
Trend fit Trend inactive -12.9% over four weeks
Fair value 30.1% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 18
Neutral 35
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 54
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 10
Ad-hoc-news.de 8
TradingView 6
GlobeNewswire 6
Quiver Quantitative 4
Market source 4
Insider Monkey 3
Simply Wall Street 2

Event Lens

What the news is about

Classified themes
Market update 36
Earnings 13
Macro sensitivity 1
Analyst action 1
Regulatory and legal 1
Balance sheet 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 54
TradingView Direct company coverage

Enterprise value to revenue forward of Insight Molecular Diagnostics Inc. – NASDAQ:IMDX

This article provides financial information for Insight Molecular Diagnostics Inc. (NASDAQ: IMDX), specifically focusing on its enterprise value to revenue forward. The content, sourced from TradingView, indicates a market closed status with no trades and highlights financial dat

Tone
Neutral 50/100
Event
Earnings
Published
20 Jul 2026 06:40
Source
TradingView
Pluang Direct company coverage

Medicare expands coverage for transplant monitoring test, boosting Insight Molecular Diagnostics' GraftAssure adoption.

Medicare has expanded its coverage for donor-derived cell-free DNA (dd-cfDNA) testing, which will increase patient access and testing frequency for kidney and heart transplant recipients. This policy change will benefit Insight Molecular Diagnostics (iMDx) and its GraftAssure tra

Tone
Neutral 50/100
Event
Market update
Published
16 Jul 2026 20:11
Source
Pluang
Quiver Quantitative Direct company coverage

iMDx Highlights Expanded Medicare Coverage for Donor-Derived Cell-Free DNA Transplant Testing

Insight Molecular Diagnostics Inc. (iMDx) announced that Medicare has expanded coverage for donor-derived cell-free DNA (dd-cfDNA) testing in transplant care, a move expected to boost the commercial adoption of its GraftAssure™ assays. The new MolDX policy clarifies reimbursement

Tone
Positive 71/100
Event
Market update
Published
16 Jul 2026 19:30
Source
Quiver Quantitative
GlobeNewswire Direct company coverage

Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio

Insight Molecular Diagnostics Inc. (iMDx) has announced a favorable new Medicare policy that significantly expands coverage for donor-derived cell-free DNA (dd-cfDNA) testing in transplant care. This policy clarifies reimbursement guidelines, increases testing frequencies for tra

Tone
Positive 73/100
Event
Market update
Published
16 Jul 2026 15:22
Source
GlobeNewswire
TradingView Direct company coverage

Price to book forward of Insight Molecular Diagnostics Inc. – NASDAQ:IMDX

This article provides financial information for Insight Molecular Diagnostics Inc. (NASDAQ: IMDX), specifically focusing on its "Price to book forward" metric. It appears to be an entry from a financial data platform, giving a snapshot of the company's valuation for investors.

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 10:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Insight Molecular Diagnostics Inc. – NASDAQ:IMDX

The article provides a financial statistic, specifically the Enterprise Value to EBIT (Earnings Before Interest and Taxes) forward for Insight Molecular Diagnostics Inc. (NASDAQ:IMDX). It appears to be a stub or a data point from a financial platform like TradingView, indicating

Tone
Neutral 50/100
Event
Earnings
Published
12 Jul 2026 07:39
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Insight Molecular Diagnostics Inc. – NASDAQ:IMDX

This article provides a specific financial metric, "Price to sales forward," for Insight Molecular Diagnostics Inc. (NASDAQ: IMDX). The content is primarily a listing from TradingView, highlighting the company's stock information, along with various platform features and disclaim

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 12:40
Source
TradingView
Investing.com Nigeria Direct company coverage

Form 4 Insight Molecular Diagnostics Inc For: 6 July By Investing.com

This article from Investing.com reports on a Form 4 filing for Molecular Diagnostics Inc. on July 6th, 2026. The filing indicates insider transaction activity for the company, which is trading down 12.59% (IMDX). The article provides no further details on the nature of the Form 4

Tone
Negative 32/100
Event
Market update
Published
07 Jul 2026 04:39
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Director Lou Silverman has IMDX shares withheld for taxes (NASDAQ: IMDX)

Insight Molecular Diagnostics Inc. director Lou Silverman reported that 7,700 shares of common stock, valued at $5.69 per share, were withheld to cover tax obligations arising from the vesting of 35,000 restricted stock units. This was not a market sale, but a routine tax-related

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 01:10
Source
Stock Titan
Stock Titan Direct company coverage

Insight Molecular (IMDX) director uses 12,100 shares to cover RSU tax withholding

Insight Molecular Diagnostics Inc. director Arno Andrew reported that 12,100 shares of Common Stock, valued at $5.69 per share, were withheld by the company to cover tax obligations related to the vesting of 55,000 restricted stock units. Critically, Andrew did not sell any share

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 01:10
Source
Stock Titan
Stock Titan Direct company coverage

Insight Molecular Diagnostics (Nasdaq: IMDX) details director RSU tax withholding

Insight Molecular Diagnostics director Andrew J. Last reported a tax-withholding transaction related to vested restricted stock units (RSUs). For tax obligations on 35,000 RSUs, 7,700 shares of common stock were withheld at $5.69 per share. This was not an open-market sale, and L

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 01:10
Source
Stock Titan
Stock Titan Direct company coverage

If You Invested $1,000 in Insight Molecular Diagnostics Inc. (IMDX)

This article examines the hypothetical return on a $1,000 investment in Insight Molecular Diagnostics Inc. (IMDX). It shows that an investment made one year ago would now be worth $1,694, representing a 69.4% total return. The piece also provides a detailed overview of the compan

Tone
Positive 66/100
Event
Market update
Published
06 Jul 2026 04:39
Source
Stock Titan
Finviz Direct company coverage

IMDX - Insight Molecular Diagnostics Inc Website Traffic and Mobile Apps Usage

This article provides a detailed financial overview of Insight Molecular Diagnostics Inc. (IMDX), including stock performance, key financial metrics, recent news, and insider trading activity. It highlights the company's focus on diagnostic tests for cancer and transplant monitor

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 11:09
Source
Finviz
Simply Wall Street Direct company coverage

Insight Molecular Diagnostics (Nasdaq:IMDX) - Stock Analysis

Insight Molecular Diagnostics (IMDX) operates as a precision diagnostics company with a market cap of US$183.7 million. While the company faces risks such as a highly volatile share price, negative shareholder equity, unprofitability, and minimal revenue, it anticipates significa

Tone
Positive 64/100
Event
Earnings
Published
01 Jul 2026 14:39
Source
Simply Wall Street
GlobeNewswire Direct company coverage

IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper

Insight Molecular Diagnostics Inc. (iMDx) announced that its Chief Science Officer, Prof. Dr. Ekkehard Schuetz, has published his 200th scientific article. Dr. Schuetz is a co-inventor of the dd-cfDNA testing technology used in iMDx’s GraftAssure assays and is recognized as a top

Tone
Positive 93/100
Event
Market update
Published
29 Jun 2026 12:09
Source
GlobeNewswire
Stock Titan Direct company coverage

iMDx science chief hits 200 papers as transplant test work builds

Insight Molecular Diagnostics (iMDx) announced that its Chief Science Officer, Prof. Dr. Ekkehard Schuetz, has published his 200th scientific article. Dr. Schuetz co-invented the dd-cfDNA technology central to iMDx's GraftAssure assays, which are designed for transplant rejection

Tone
Positive 71/100
Event
Market update
Published
29 Jun 2026 12:09
Source
Stock Titan
TradingView Direct company coverage

Insight Molecular Diagnostics Inc. Actuals & Estimates (NASDAQ:IMDX)

This article provides an overview of Insight Molecular Diagnostics Inc. (NASDAQ: IMDX), detailing its current stock price, historical performance, and analyst forecasts. It includes key financial data like market capitalization, earnings per share, and revenue, along with employe

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 13:13
Source
TradingView
TradingView Direct company coverage

Insight Molecular Diagnostics Inc. Actuals & Estimates (BOATS:IMDX)

This article provides an overview of Insight Molecular Diagnostics Inc. (IMDX) financial actuals and analyst estimates, including income statement, balance sheet, and cash flow data. It covers stock performance, earnings reports, revenue, net income, and EBITDA, along with freque

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 19:39
Source
TradingView
Simply Wall Street Direct company coverage

IMDX: FDA Review And New Transplant Data Will Drive Bullish Repricing

Insight Molecular Diagnostics (IMDX) is poised for a significant repricing due to its GraftAssure transplant monitoring test. Recent Clinical Chemistry and American Journal of Transplantation articles highlight its high concordance, diagnostic performance, and potential for earli

Tone
Positive 81/100
Event
Market update
Published
25 Jun 2026 02:09
Source
Simply Wall Street
Stock Titan Direct company coverage

iMDx and ASTS fund $100,000 study on kidney transplant testing costs

Insight Molecular Diagnostics (iMDx) and the American Society of Transplant Surgeons (ASTS) have awarded a $100,000 research grant to Drs. Kenneth Andreoni and Kenneth Chavin. Their study will compare the health economics of in-house versus send-out donor-derived cell-free DNA (d

Tone
Positive 73/100
Event
Market update
Published
22 Jun 2026 17:41
Source
Stock Titan
GlobeNewswire Direct company coverage

iMDx and the American Society of Transplant Surgeons

Insight Molecular Diagnostics Inc. (iMDx) and the American Society of Transplant Surgeons (ASTS) announced Dr. Kenneth Andreoni and Dr. Kenneth Chavin as recipients of a $100,000 grant. This grant supports research into the health economics of in-house versus send-out donor-deriv

Tone
Positive 75/100
Event
Market update
Published
22 Jun 2026 14:07
Source
GlobeNewswire